Media-OutReach Newswire China Dongxiang Announces Interim Results for the First Half of 2018 Reforms Continued with High Dividend Payout Maintained
Media-OutReach Newswire Sihuan Pharmaceutical’s Self-Developed Innovative Oncology Drug Pirotinib Commenced Phase II Clinical Trial in China